EYPT News and Press, EyePoint Pharmaceuticals Inc. From 11/02/22

EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q3 GAAP EPS of -$0.49 beats by $0.16 . Revenue of $10.01M (+10.5% Y/Y) misses by $0.91M . Cash and investments at September 30, 2022 totaled $157.3 million compared to $171.2 million at June 30, 2022. ...

– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive twelve-month safety and efficacy data from Phase 1 DA...

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...

WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the first patient has been ...

NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GrafTech International Ltd. (NYSE: EAF), EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), Vintage Wine Estates, Inc. (NA...

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GrafTech International Ltd. (NYSE: EAF), Polished.com, Inc. (NYSEAmerican: POL), EyePoint Pharmaceuticals, Inc. (NASDA...

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief Executive Officer Jay Duker - Chief Operating Officer Scott Jones ...

EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q2 GAAP EPS of -$0.52 misses by $0.01 . Revenue of $11.6M (+28.7% Y/Y) beats by $0.74M . "We expect the cash, cash equivalents and investments on hand on June 30, 2022 and expected net cash inflows from o...

– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Societ...

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD PR Newswire -Topline data expected in the second half of 2023- WATERTOWN, Mass. , Aug. 1, 2022 /PRNewswir...